(Q42833589)

8 November 2017

title

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer (English)

1 reference

8 November 2017

1 reference

1 reference

1

Fred Saad

1 reference

8 November 2017

James Eastham

2

1 reference

8 November 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

8 November 2017

1 reference

8 November 2017

volume

76

1 reference

8 November 2017

issue

5

1 reference

8 November 2017

page(s)

1175-1181

1 reference

8 November 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Role of pamidronate disodium in the treatment of metastatic bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Bisphosphonates for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

The safety of zoledronic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Cancer treatment-induced bone loss in breast and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2010.05.026

10.1016/J.UROLOGY.2010.05.026

7 January 2021

Identifiers

DOI

1 reference

8 November 2017

1 reference